

Global Endogenous Peptide Substances Supply, Demand and Key Producers, 2023-2029

https://marketpublishers.com/r/G6E7923CC4C3EN.html

Date: November 2023

Pages: 109

Price: US\$ 4,480.00 (Single User License)

ID: G6E7923CC4C3EN

Abstracts

The global Endogenous Peptide Substances market size is expected to reach \$ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

The driving force of endogenous peptides mainly comes from the following aspects:

Biological functions of bioactive peptides: Bioactive peptides have a variety of biological functions, such as neuromodulation, immune regulation, anti-inflammation, anti-tumor, etc. These functions play an important role in maintaining normal physiological functions and health of the human body. For example, endorphins have analgesic effects and can relieve pain, while growth hormone-releasing hormone can stimulate the secretion of growth hormone and regulate the growth and development of the human body. These functions enable endogenous peptides to play important physiological roles in the human body.

Demand for drug research and development: With the development of medical technology, people's demand for drugs is getting higher and higher. As an important type of biological drugs, peptide drugs are receiving more and more attention in their research and development and application. Peptide drugs have many advantages, such as high efficiency, low toxicity, and good biocompatibility. Therefore, they are widely used in anti-tumor, anti-infection, neurological diseases and other fields. As an important source of peptide drugs, endogenous peptides have received more attention in their development and utilization.

Progress in production technology: Since the chemical structure and biological activity of endogenous peptides are strictly protected, special attention needs to be paid to maintaining their original biological activity during production and processing. With the



continuous advancement of production technology, people have explored more efficient and safer preparation methods, which has greatly improved the production efficiency of endogenous peptides and reduced costs.

Expansion of indications: As the research and development of endogenous peptides continues to deepen, their indications are also expanding. For example, insulin is an important drug in the treatment of diabetes, while growth hormone is widely used in antiaging and other fields. The expansion of these indications has led to an increasing demand for endogenous peptides.

This report studies the global Endogenous Peptide Substances demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Endogenous Peptide Substances, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Endogenous Peptide Substances that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Endogenous Peptide Substances total market, 2018-2029, (USD Million)

Global Endogenous Peptide Substances total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Endogenous Peptide Substances total market, key domestic companies and share, (USD Million)

Global Endogenous Peptide Substances revenue by player and market share 2018-2023, (USD Million)

Global Endogenous Peptide Substances total market by Type, CAGR, 2018-2029, (USD Million)

Global Endogenous Peptide Substances total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global Endogenous Peptide Substances



market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Assertio Therapeutics Inc., Cipher Pharmaceuticals Inc., Endo International Plc, Biosynth Carbosynth, Lannett Co. Inc., Pfizer, Johnson & Johnson, Peptide Institute and Abbexa, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Endogenous Peptide Substances market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Endogenous Peptide Substances Market, By Region:

United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Endogenous Peptide Substances Market, Segmentation by Type



| | Neuropeptides |
|--------|---|
| | Hormones |
| | Cytokines |
| | Peptide Hormones |
| | Bioactive Peptides |
| Global | Endogenous Peptide Substances Market, Segmentation by Application |
| | Research |
| | Medicine |
| | Others |
| Compa | nies Profiled: |
| | Assertio Therapeutics Inc. |
| | Cipher Pharmaceuticals Inc. |
| | Endo International Plc |
| | Biosynth Carbosynth |
| | Lannett Co. Inc. |
| | Pfizer |
| | Johnson & Johnson |
| | Peptide Institute |
| | Abbexa |



Phoenix Pharmaceuticals

Creative Peptides

Key Questions Answered

- 1. How big is the global Endogenous Peptide Substances market?
- 2. What is the demand of the global Endogenous Peptide Substances market?
- 3. What is the year over year growth of the global Endogenous Peptide Substances market?
- 4. What is the total value of the global Endogenous Peptide Substances market?
- 5. Who are the major players in the global Endogenous Peptide Substances market?



Contents

1 SUPPLY SUMMARY

- 1.1 Endogenous Peptide Substances Introduction
- 1.2 World Endogenous Peptide Substances Market Size & Forecast (2018 & 2022 & 2029)
- 1.3 World Endogenous Peptide Substances Total Market by Region (by Headquarter Location)
- 1.3.1 World Endogenous Peptide Substances Market Size by Region (2018-2029), (by Headquarter Location)
 - 1.3.2 United States Endogenous Peptide Substances Market Size (2018-2029)
 - 1.3.3 China Endogenous Peptide Substances Market Size (2018-2029)
 - 1.3.4 Europe Endogenous Peptide Substances Market Size (2018-2029)
 - 1.3.5 Japan Endogenous Peptide Substances Market Size (2018-2029)
 - 1.3.6 South Korea Endogenous Peptide Substances Market Size (2018-2029)
 - 1.3.7 ASEAN Endogenous Peptide Substances Market Size (2018-2029)
 - 1.3.8 India Endogenous Peptide Substances Market Size (2018-2029)
- 1.4 Market Drivers, Restraints and Trends
 - 1.4.1 Endogenous Peptide Substances Market Drivers
 - 1.4.2 Factors Affecting Demand
 - 1.4.3 Endogenous Peptide Substances Major Market Trends

2 DEMAND SUMMARY

- 2.1 World Endogenous Peptide Substances Consumption Value (2018-2029)
- 2.2 World Endogenous Peptide Substances Consumption Value by Region
- 2.2.1 World Endogenous Peptide Substances Consumption Value by Region (2018-2023)
- 2.2.2 World Endogenous Peptide Substances Consumption Value Forecast by Region (2024-2029)
- 2.3 United States Endogenous Peptide Substances Consumption Value (2018-2029)
- 2.4 China Endogenous Peptide Substances Consumption Value (2018-2029)
- 2.5 Europe Endogenous Peptide Substances Consumption Value (2018-2029)
- 2.6 Japan Endogenous Peptide Substances Consumption Value (2018-2029)
- 2.7 South Korea Endogenous Peptide Substances Consumption Value (2018-2029)
- 2.8 ASEAN Endogenous Peptide Substances Consumption Value (2018-2029)
- 2.9 India Endogenous Peptide Substances Consumption Value (2018-2029)



3 WORLD ENDOGENOUS PEPTIDE SUBSTANCES COMPANIES COMPETITIVE ANALYSIS

- 3.1 World Endogenous Peptide Substances Revenue by Player (2018-2023)
- 3.2 Industry Rank and Concentration Rate (CR)
- 3.2.1 Global Endogenous Peptide Substances Industry Rank of Major Players
- 3.2.2 Global Concentration Ratios (CR4) for Endogenous Peptide Substances in 2022
- 3.2.3 Global Concentration Ratios (CR8) for Endogenous Peptide Substances in 2022
- 3.3 Endogenous Peptide Substances Company Evaluation Quadrant
- 3.4 Endogenous Peptide Substances Market: Overall Company Footprint Analysis
 - 3.4.1 Endogenous Peptide Substances Market: Region Footprint
- 3.4.2 Endogenous Peptide Substances Market: Company Product Type Footprint
- 3.4.3 Endogenous Peptide Substances Market: Company Product Application Footprint
- 3.5 Competitive Environment
 - 3.5.1 Historical Structure of the Industry
 - 3.5.2 Barriers of Market Entry
 - 3.5.3 Factors of Competition
- 3.6 Mergers, Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)

- 4.1 United States VS China: Endogenous Peptide Substances Revenue Comparison (by Headquarter Location)
- 4.1.1 United States VS China: Endogenous Peptide Substances Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
- 4.1.2 United States VS China: Endogenous Peptide Substances Revenue Market Share Comparison (2018 & 2022 & 2029)
- 4.2 United States Based Companies VS China Based Companies: Endogenous Peptide Substances Consumption Value Comparison
- 4.2.1 United States VS China: Endogenous Peptide Substances Consumption Value Comparison (2018 & 2022 & 2029)
- 4.2.2 United States VS China: Endogenous Peptide Substances Consumption Value Market Share Comparison (2018 & 2022 & 2029)
- 4.3 United States Based Endogenous Peptide Substances Companies and Market Share, 2018-2023
- 4.3.1 United States Based Endogenous Peptide Substances Companies, Headquarters (States, Country)



- 4.3.2 United States Based Companies Endogenous Peptide Substances Revenue, (2018-2023)
- 4.4 China Based Companies Endogenous Peptide Substances Revenue and Market Share, 2018-2023
- 4.4.1 China Based Endogenous Peptide Substances Companies, Company Headquarters (Province, Country)
- 4.4.2 China Based Companies Endogenous Peptide Substances Revenue, (2018-2023)
- 4.5 Rest of World Based Endogenous Peptide Substances Companies and Market Share, 2018-2023
- 4.5.1 Rest of World Based Endogenous Peptide Substances Companies, Headquarters (States, Country)
- 4.5.2 Rest of World Based Companies Endogenous Peptide Substances Revenue, (2018-2023)

5 MARKET ANALYSIS BY TYPE

- 5.1 World Endogenous Peptide Substances Market Size Overview by Type: 2018 VS 2022 VS 2029
- 5.2 Segment Introduction by Type
 - 5.2.1 Neuropeptides
 - 5.2.2 Hormones
 - 5.2.3 Cytokines
 - 5.2.4 Peptide Hormones
 - 5.2.5 Bioactive Peptides
- 5.3 Market Segment by Type
 - 5.3.1 World Endogenous Peptide Substances Market Size by Type (2018-2023)
 - 5.3.2 World Endogenous Peptide Substances Market Size by Type (2024-2029)
- 5.3.3 World Endogenous Peptide Substances Market Size Market Share by Type (2018-2029)

6 MARKET ANALYSIS BY APPLICATION

- 6.1 World Endogenous Peptide Substances Market Size Overview by Application: 2018 VS 2022 VS 2029
- 6.2 Segment Introduction by Application
 - 6.2.1 Research
 - 6.2.2 Medicine
 - 6.2.3 Others



- 6.3 Market Segment by Application
 - 6.3.1 World Endogenous Peptide Substances Market Size by Application (2018-2023)
 - 6.3.2 World Endogenous Peptide Substances Market Size by Application (2024-2029)
 - 6.3.3 World Endogenous Peptide Substances Market Size by Application (2018-2029)

7 COMPANY PROFILES

- 7.1 Assertio Therapeutics Inc.
 - 7.1.1 Assertio Therapeutics Inc. Details
 - 7.1.2 Assertio Therapeutics Inc. Major Business
- 7.1.3 Assertio Therapeutics Inc. Endogenous Peptide Substances Product and Services
- 7.1.4 Assertio Therapeutics Inc. Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
 - 7.1.5 Assertio Therapeutics Inc. Recent Developments/Updates
 - 7.1.6 Assertio Therapeutics Inc. Competitive Strengths & Weaknesses
- 7.2 Cipher Pharmaceuticals Inc.
 - 7.2.1 Cipher Pharmaceuticals Inc. Details
 - 7.2.2 Cipher Pharmaceuticals Inc. Major Business
- 7.2.3 Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Product and Services
- 7.2.4 Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
 - 7.2.5 Cipher Pharmaceuticals Inc. Recent Developments/Updates
 - 7.2.6 Cipher Pharmaceuticals Inc. Competitive Strengths & Weaknesses
- 7.3 Endo International Plc
 - 7.3.1 Endo International Plc Details
 - 7.3.2 Endo International Plc Major Business
 - 7.3.3 Endo International Plc Endogenous Peptide Substances Product and Services
- 7.3.4 Endo International Plc Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
 - 7.3.5 Endo International Plc Recent Developments/Updates
 - 7.3.6 Endo International Plc Competitive Strengths & Weaknesses
- 7.4 Biosynth Carbosynth
- 7.4.1 Biosynth Carbosynth Details
- 7.4.2 Biosynth Carbosynth Major Business
- 7.4.3 Biosynth Carbosynth Endogenous Peptide Substances Product and Services
- 7.4.4 Biosynth Carbosynth Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)



- 7.4.5 Biosynth Carbosynth Recent Developments/Updates
- 7.4.6 Biosynth Carbosynth Competitive Strengths & Weaknesses
- 7.5 Lannett Co. Inc.
 - 7.5.1 Lannett Co. Inc. Details
 - 7.5.2 Lannett Co. Inc. Major Business
 - 7.5.3 Lannett Co. Inc. Endogenous Peptide Substances Product and Services
- 7.5.4 Lannett Co. Inc. Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
 - 7.5.5 Lannett Co. Inc. Recent Developments/Updates
 - 7.5.6 Lannett Co. Inc. Competitive Strengths & Weaknesses
- 7.6 Pfizer
 - 7.6.1 Pfizer Details
 - 7.6.2 Pfizer Major Business
 - 7.6.3 Pfizer Endogenous Peptide Substances Product and Services
- 7.6.4 Pfizer Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
 - 7.6.5 Pfizer Recent Developments/Updates
- 7.6.6 Pfizer Competitive Strengths & Weaknesses
- 7.7 Johnson & Johnson
 - 7.7.1 Johnson & Johnson Details
 - 7.7.2 Johnson & Johnson Major Business
 - 7.7.3 Johnson & Johnson Endogenous Peptide Substances Product and Services
- 7.7.4 Johnson & Johnson Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
 - 7.7.5 Johnson & Johnson Recent Developments/Updates
 - 7.7.6 Johnson & Johnson Competitive Strengths & Weaknesses
- 7.8 Peptide Institute
 - 7.8.1 Peptide Institute Details
 - 7.8.2 Peptide Institute Major Business
 - 7.8.3 Peptide Institute Endogenous Peptide Substances Product and Services
- 7.8.4 Peptide Institute Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
 - 7.8.5 Peptide Institute Recent Developments/Updates
 - 7.8.6 Peptide Institute Competitive Strengths & Weaknesses
- 7.9 Abbexa
 - 7.9.1 Abbexa Details
 - 7.9.2 Abbexa Major Business
 - 7.9.3 Abbexa Endogenous Peptide Substances Product and Services
- 7.9.4 Abbexa Endogenous Peptide Substances Revenue, Gross Margin and Market



Share (2018-2023)

- 7.9.5 Abbexa Recent Developments/Updates
- 7.9.6 Abbexa Competitive Strengths & Weaknesses
- 7.10 Phoenix Pharmaceuticals
 - 7.10.1 Phoenix Pharmaceuticals Details
 - 7.10.2 Phoenix Pharmaceuticals Major Business
- 7.10.3 Phoenix Pharmaceuticals Endogenous Peptide Substances Product and Services
- 7.10.4 Phoenix Pharmaceuticals Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
 - 7.10.5 Phoenix Pharmaceuticals Recent Developments/Updates
 - 7.10.6 Phoenix Pharmaceuticals Competitive Strengths & Weaknesses
- 7.11 Creative Peptides
 - 7.11.1 Creative Peptides Details
 - 7.11.2 Creative Peptides Major Business
 - 7.11.3 Creative Peptides Endogenous Peptide Substances Product and Services
- 7.11.4 Creative Peptides Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
 - 7.11.5 Creative Peptides Recent Developments/Updates
 - 7.11.6 Creative Peptides Competitive Strengths & Weaknesses

8 INDUSTRY CHAIN ANALYSIS

- 8.1 Endogenous Peptide Substances Industry Chain
- 8.2 Endogenous Peptide Substances Upstream Analysis
- 8.3 Endogenous Peptide Substances Midstream Analysis
- 8.4 Endogenous Peptide Substances Downstream Analysis

9 RESEARCH FINDINGS AND CONCLUSION

10 APPENDIX

- 10.1 Methodology
- 10.2 Research Process and Data Source
- 10.3 Disclaimer



List Of Tables

LIST OF TABLES

- Table 1. World Endogenous Peptide Substances Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
- Table 2. World Endogenous Peptide Substances Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
- Table 3. World Endogenous Peptide Substances Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
- Table 4. World Endogenous Peptide Substances Revenue Market Share by Region (2018-2023), (by Headquarter Location)
- Table 5. World Endogenous Peptide Substances Revenue Market Share by Region (2024-2029), (by Headquarter Location)
- Table 6. Major Market Trends
- Table 7. World Endogenous Peptide Substances Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
- Table 8. World Endogenous Peptide Substances Consumption Value by Region (2018-2023) & (USD Million)
- Table 9. World Endogenous Peptide Substances Consumption Value Forecast by Region (2024-2029) & (USD Million)
- Table 10. World Endogenous Peptide Substances Revenue by Player (2018-2023) & (USD Million)
- Table 11. Revenue Market Share of Key Endogenous Peptide Substances Players in 2022
- Table 12. World Endogenous Peptide Substances Industry Rank of Major Player, Based on Revenue in 2022
- Table 13. Global Endogenous Peptide Substances Company Evaluation Quadrant
- Table 14. Head Office of Key Endogenous Peptide Substances Player
- Table 15. Endogenous Peptide Substances Market: Company Product Type Footprint
- Table 16. Endogenous Peptide Substances Market: Company Product Application Footprint
- Table 17. Endogenous Peptide Substances Mergers & Acquisitions Activity
- Table 18. United States VS China Endogenous Peptide Substances Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
- Table 19. United States VS China Endogenous Peptide Substances Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
- Table 20. United States Based Endogenous Peptide Substances Companies, Headquarters (States, Country)



- Table 21. United States Based Companies Endogenous Peptide Substances Revenue, (2018-2023) & (USD Million)
- Table 22. United States Based Companies Endogenous Peptide Substances Revenue Market Share (2018-2023)
- Table 23. China Based Endogenous Peptide Substances Companies, Headquarters (Province, Country)
- Table 24. China Based Companies Endogenous Peptide Substances Revenue, (2018-2023) & (USD Million)
- Table 25. China Based Companies Endogenous Peptide Substances Revenue Market Share (2018-2023)
- Table 26. Rest of World Based Endogenous Peptide Substances Companies, Headquarters (States, Country)
- Table 27. Rest of World Based Companies Endogenous Peptide Substances Revenue, (2018-2023) & (USD Million)
- Table 28. Rest of World Based Companies Endogenous Peptide Substances Revenue Market Share (2018-2023)
- Table 29. World Endogenous Peptide Substances Market Size by Type, (USD Million), 2018 & 2022 & 2029
- Table 30. World Endogenous Peptide Substances Market Size by Type (2018-2023) & (USD Million)
- Table 31. World Endogenous Peptide Substances Market Size by Type (2024-2029) & (USD Million)
- Table 32. World Endogenous Peptide Substances Market Size by Application, (USD Million), 2018 & 2022 & 2029
- Table 33. World Endogenous Peptide Substances Market Size by Application (2018-2023) & (USD Million)
- Table 34. World Endogenous Peptide Substances Market Size by Application (2024-2029) & (USD Million)
- Table 35. Assertio Therapeutics Inc. Basic Information, Area Served and Competitors
- Table 36. Assertio Therapeutics Inc. Major Business
- Table 37. Assertio Therapeutics Inc. Endogenous Peptide Substances Product and Services
- Table 38. Assertio Therapeutics Inc. Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 39. Assertio Therapeutics Inc. Recent Developments/Updates
- Table 40. Assertio Therapeutics Inc. Competitive Strengths & Weaknesses
- Table 41. Cipher Pharmaceuticals Inc. Basic Information, Area Served and Competitors
- Table 42. Cipher Pharmaceuticals Inc. Major Business
- Table 43. Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Product and



Services

Table 44. Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Revenue,

Gross Margin and Market Share (2018-2023) & (USD Million)

Table 45. Cipher Pharmaceuticals Inc. Recent Developments/Updates

Table 46. Cipher Pharmaceuticals Inc. Competitive Strengths & Weaknesses

Table 47. Endo International Plc Basic Information, Area Served and Competitors

Table 48. Endo International Plc Major Business

Table 49. Endo International Plc Endogenous Peptide Substances Product and Services

Table 50. Endo International Plc Endogenous Peptide Substances Revenue, Gross

Margin and Market Share (2018-2023) & (USD Million)

Table 51. Endo International Plc Recent Developments/Updates

Table 52. Endo International Plc Competitive Strengths & Weaknesses

Table 53. Biosynth Carbosynth Basic Information, Area Served and Competitors

Table 54. Biosynth Carbosynth Major Business

Table 55. Biosynth Carbosynth Endogenous Peptide Substances Product and Services

Table 56. Biosynth Carbosynth Endogenous Peptide Substances Revenue, Gross

Margin and Market Share (2018-2023) & (USD Million)

Table 57. Biosynth Carbosynth Recent Developments/Updates

Table 58. Biosynth Carbosynth Competitive Strengths & Weaknesses

Table 59. Lannett Co. Inc. Basic Information, Area Served and Competitors

Table 60. Lannett Co. Inc. Major Business

Table 61. Lannett Co. Inc. Endogenous Peptide Substances Product and Services

Table 62. Lannett Co. Inc. Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 63. Lannett Co. Inc. Recent Developments/Updates

Table 64. Lannett Co. Inc. Competitive Strengths & Weaknesses

Table 65. Pfizer Basic Information, Area Served and Competitors

Table 66. Pfizer Major Business

Table 67. Pfizer Endogenous Peptide Substances Product and Services

Table 68. Pfizer Endogenous Peptide Substances Revenue, Gross Margin and Market

Share (2018-2023) & (USD Million)

Table 69. Pfizer Recent Developments/Updates

Table 70. Pfizer Competitive Strengths & Weaknesses

Table 71. Johnson & Johnson Basic Information, Area Served and Competitors

Table 72. Johnson & Johnson Major Business

Table 73. Johnson & Johnson Endogenous Peptide Substances Product and Services

Table 74. Johnson & Johnson Endogenous Peptide Substances Revenue, Gross

Margin and Market Share (2018-2023) & (USD Million)



- Table 75. Johnson & Johnson Recent Developments/Updates
- Table 76. Johnson & Johnson Competitive Strengths & Weaknesses
- Table 77. Peptide Institute Basic Information, Area Served and Competitors
- Table 78. Peptide Institute Major Business
- Table 79. Peptide Institute Endogenous Peptide Substances Product and Services
- Table 80. Peptide Institute Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 81. Peptide Institute Recent Developments/Updates
- Table 82. Peptide Institute Competitive Strengths & Weaknesses
- Table 83. Abbexa Basic Information, Area Served and Competitors
- Table 84. Abbexa Major Business
- Table 85. Abbexa Endogenous Peptide Substances Product and Services
- Table 86. Abbexa Endogenous Peptide Substances Revenue, Gross Margin and
- Market Share (2018-2023) & (USD Million)
- Table 87. Abbexa Recent Developments/Updates
- Table 88. Abbexa Competitive Strengths & Weaknesses
- Table 89. Phoenix Pharmaceuticals Basic Information, Area Served and Competitors
- Table 90. Phoenix Pharmaceuticals Major Business
- Table 91. Phoenix Pharmaceuticals Endogenous Peptide Substances Product and Services
- Table 92. Phoenix Pharmaceuticals Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 93. Phoenix Pharmaceuticals Recent Developments/Updates
- Table 94. Creative Peptides Basic Information, Area Served and Competitors
- Table 95. Creative Peptides Major Business
- Table 96. Creative Peptides Endogenous Peptide Substances Product and Services
- Table 97. Creative Peptides Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 98. Global Key Players of Endogenous Peptide Substances Upstream (Raw Materials)
- Table 99. Endogenous Peptide Substances Typical Customers

LIST OF FIGURE

- Figure 1. Endogenous Peptide Substances Picture
- Figure 2. World Endogenous Peptide Substances Total Market Size: 2018 & 2022 & 2029, (USD Million)
- Figure 3. World Endogenous Peptide Substances Total Market Size (2018-2029) & (USD Million)



Figure 4. World Endogenous Peptide Substances Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)

Figure 5. World Endogenous Peptide Substances Revenue Market Share by Region (2018-2029), (by Headquarter Location)

Figure 6. United States Based Company Endogenous Peptide Substances Revenue (2018-2029) & (USD Million)

Figure 7. China Based Company Endogenous Peptide Substances Revenue (2018-2029) & (USD Million)

Figure 8. Europe Based Company Endogenous Peptide Substances Revenue (2018-2029) & (USD Million)

Figure 9. Japan Based Company Endogenous Peptide Substances Revenue (2018-2029) & (USD Million)

Figure 10. South Korea Based Company Endogenous Peptide Substances Revenue (2018-2029) & (USD Million)

Figure 11. ASEAN Based Company Endogenous Peptide Substances Revenue (2018-2029) & (USD Million)

Figure 12. India Based Company Endogenous Peptide Substances Revenue (2018-2029) & (USD Million)

Figure 13. Endogenous Peptide Substances Market Drivers

Figure 14. Factors Affecting Demand

Figure 15. World Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)

Figure 16. World Endogenous Peptide Substances Consumption Value Market Share by Region (2018-2029)

Figure 17. United States Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)

Figure 18. China Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)

Figure 19. Europe Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)

Figure 20. Japan Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)

Figure 21. South Korea Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)

Figure 22. ASEAN Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)

Figure 23. India Endogenous Peptide Substances Consumption Value (2018-2029) & (USD Million)

Figure 24. Producer Shipments of Endogenous Peptide Substances by Player Revenue



(\$MM) and Market Share (%): 2022

Figure 25. Global Four-firm Concentration Ratios (CR4) for Endogenous Peptide Substances Markets in 2022

Figure 26. Global Four-firm Concentration Ratios (CR8) for Endogenous Peptide Substances Markets in 2022

Figure 27. United States VS China: Endogenous Peptide Substances Revenue Market Share Comparison (2018 & 2022 & 2029)

Figure 28. United States VS China: Endogenous Peptide Substances Consumption Value Market Share Comparison (2018 & 2022 & 2029)

Figure 29. World Endogenous Peptide Substances Market Size by Type, (USD Million), 2018 & 2022 & 2029

Figure 30. World Endogenous Peptide Substances Market Size Market Share by Type in 2022

Figure 31. Neuropeptides

Figure 32. Hormones

Figure 33. Cytokines

Figure 34. Peptide Hormones

Figure 35. Bioactive Peptides

Figure 36. World Endogenous Peptide Substances Market Size Market Share by Type (2018-2029)

Figure 37. World Endogenous Peptide Substances Market Size by Application, (USD Million), 2018 & 2022 & 2029

Figure 38. World Endogenous Peptide Substances Market Size Market Share by Application in 2022

Figure 39. Research

Figure 40. Medicine

Figure 41. Others

Figure 42. Endogenous Peptide Substances Industrial Chain

Figure 43. Methodology

Figure 44. Research Process and Data Source



I would like to order

Product name: Global Endogenous Peptide Substances Supply, Demand and Key Producers, 2023-2029

Product link: https://marketpublishers.com/r/G6E7923CC4C3EN.html

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G6E7923CC4C3EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

| First name: | |
|---------------|---------------------------|
| Last name: | |
| Email: | |
| Company: | |
| Address: | |
| City: | |
| Zip code: | |
| Country: | |
| Tel: | |
| Fax: | |
| Your message: | |
| | |
| | |
| | |
| | **All fields are required |
| | Custumer signature |
| | |
| | |

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970